PECULIARITIES OF TREATMENT IN PATIENTS WITH ENDOMETRIAL HYPERPLASTIC PROCESSES AND HYPOTHYROIDISM
К ВОПРОСУ О РАЦИОНАЛИЗАЦИИ ТЕРАПИИ ЖЕНЩИН С СОЧЕТАНИЕМ ГИПЕРПЛАСТИЧЕСКИХ ПРОЦЕССОВ ЭНДОМЕТРИЯ И ГИПОТИРЕОЗА
Abstract
The main goal was to determine the optimal therapy policy for endometrial hyperplastic processes (EHP) in women with hypothyroidism. In 42 women there was applied only levothyroxine; in 48 cases treatment contained the both, levothyroxine and steroid hormones. It was ascertained, that treatment for EHP in patients with hypothyroidism, first of all, should consist of correction of thyroid dysfunction.
Downloads
References
Amiraslanov A.T., Safarova S.I. Risk factors and prognostic indicators of atypical endometrial hyperplasia. Bulletin of Modern clinical medicine. 2019; 12(2): 7-11.
Binder P.S., Mutch D.G. Update on prognostic markers for endometrial cancer. Womens Health (Lond.). 2014; 10(3): 277-88.
Chekhoeva A.N., Gabaraev G.M., et all. Clinical and diagnostic aspects of and therapeutic policy for endometrial hyperplastic processes from contemporary perspectives. Bulletin of Novel Medical Technologies. Electronic Edition; 2019; 13(4): 41-9.
Costales A.B., Schmeler K.M., et all. Clinically significant endometrial cancer risk following a diagnosis of complex atypical hyperplasia. Gynecol. Oncol. 2014; 135(3): 451-4.
Kovallenko E.P. The relationship between endometrial hyperplasia and endocrine disorders in women of early and late reproductive ages. Tauride Biomedical Bulletin. Scientific and Practical journal. 2014; 17(3): 35-8.
Masyakina A.V., Kudrina E.A. Diagnosis and treatment of benign uterine hyperplastic diseases in women with endocrine and metabolic disorders. V.F.Snegirev Archive of obstetrics and Gynecology; 2015; 2(3): 20-4.
Mikhelson A.F., Lebendenko E.Yu., et all. Features of the autonomic regulation of functions in reproductive aged women with endometrial hyperplastic processes. (Head physician of the South of Russia). 2018; 3(62): 45-8.
Panshina M.V., Khadartseva K.A. Experience in preventing endometrial diseases. (Bulletin of Novel Medical Technologies); 2018; 12(3): 61-5.
Reyes H.D., Corlson M.J., et all. Downregulation of FOXO mRNA levels predicts treatment failure in patients with endometrial pathology conservatively managed with progestine-containing intrauterine devices. ,,Gynecol. Oncol.’’. 2016; 140(1): 152-60.
Rodriguez-Castelan J., Anaya-Hernandez A. et all. Distribution of thyroid hormone and thyrotropin receptors in reproductive tissues of adult female rabbits. ,,Endocr. Res.’’ 2017; 42(1): 59-70.
Silva J.F., Ocarino N.M., et all. Thyroid hormones and female reproduction. ,,Biol.. Reprod.’’, 2018; 99(5): 907-21.
Tabakman Yu. Yu., Solopova A.G. et all. Endometrial hyperplasia: controversial issues of pathogenesis and therapy. ,,Obstetrics, Gynecology and Reproduction’’; 2016; 10(3): 5-10.
Wang Y., Nisenblat V., et all. Combined estrogen-progestin pill is a safe and effective option for endometrial hyperplasia without atypia; ,,J. Gynecol. Oncol.’’ 2019; 30(3): e49.
Yunusov A.A. Thyroid homeostasis and dyshormonal disorders of the female reproductive system ,,International Endocrinology Journal;’’ 2014; 8(64): 100-6.
Zavalko A.F., Kotelnikova N.A. Endometrial hyperplasia: pathogenetic aspects, classification and prevalence of the disease among reproductive-aged patients. (Bulletin of the Medical Institute ,,Reaviz’’: Rehabilitation; Doctor and Health); 2016; 1(21): 22-7.
